Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, Inc. (NASDAQ:DNTH), filed a Form 4 on September 3, 2026, disclosing option exercises and common stock sales executed on September 1, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Three option tranches exercised: Randhawa exercised stock options covering 7,500 shares at $17.88, 6,249 shares at $21.77, and 9,375 shares at $22.07, all on September 1, 2026.
  • 23,124 shares sold: A total of 23,124 shares of common stock were disposed of across three sale transactions at weighted average prices of $105.19, $106.25, and $106.74 per share.
  • Remaining direct ownership: Following all reported transactions, Randhawa directly held 4,000 shares of common stock.
  • Rule 10b5-1 plan: According to the filing, all transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
  • Remaining derivative holdings: After the exercises, Randhawa retained 56,776, 41,676, and 87,500 stock options from the three respective tranches.

Randhawa's September 2026 Option Exercises and Stock Sales at Dianthus Therapeutics

According to the Form 4 filing, Simrat Randhawa, who serves as EVP and Head of R&D at Dianthus Therapeutics, Inc., carried out a series of transactions on September 1, 2026. The filing indicates all transactions were made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Three separate stock option grants were exercised: 7,500 shares at an exercise price of $17.88, 6,249 shares at $21.77, and 9,375 shares at $22.07, each coded as "M" transactions in the filing.

The filing also reports three sales of common stock on the same date. A total of 2,600 shares were sold at a weighted average price of $105.19 (with individual transaction prices ranging from $104.50 to $105.46), 7,215 shares at a weighted average of $106.25 (ranging from $105.53 to $106.52), and 13,309 shares at a weighted average of $106.74 (ranging from $106.53 to $107.31). The filing notes that Randhawa undertakes to provide full information on the number of shares sold at each separate price upon request by the issuer, any security holder, or the SEC staff.

After all reported transactions, the filing shows Randhawa's direct beneficial ownership stood at 4,000 shares of common stock. The three stock option awards underlying the exercised options vest in equal monthly installments over four years, with vesting commencement dates of January 1, 2024, May 1, 2024, and January 1, 2025, respectively, subject to continued service. Remaining balances on those option grants were reported as 56,776, 41,676, and 87,500 options, respectively.

What Was Disclosed

The filing disclosed option exercises and open-market stock sales by Dianthus Therapeutics' EVP and Head of R&D on September 1, 2026, all conducted under a pre-established Rule 10b5-1 plan, leaving the reporting person with a direct holding of 4,000 common shares.